Annexin Pharmaceuticals AB (ANNX) - Total Liabilities
Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has total liabilities worth Skr5.56 Million SEK (≈ $598.56K USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Annexin Pharmaceuticals AB - Total Liabilities Trend (2014–2025)
This chart illustrates how Annexin Pharmaceuticals AB's total liabilities have evolved over time, based on quarterly financial data. See ANNX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annexin Pharmaceuticals AB Competitors by Total Liabilities
The table below lists competitors of Annexin Pharmaceuticals AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Intelicare Holdings Ltd
AU:ICR
|
Australia | AU$1.86 Million |
|
Ind-Swift Limited
NSE:INDSWFTLTD
|
India | Rs11.30 Billion |
|
Sidomulyo Selaras Tbk
JK:SDMU
|
Indonesia | Rp116.09 Billion |
|
Bekasi Asri Pemula Tbk
JK:BAPA
|
Indonesia | Rp17.32 Billion |
|
Buru Energy Ltd
AU:BRU
|
Australia | AU$14.49 Million |
|
Indo Straits Tbk
JK:PTIS
|
Indonesia | Rp11.01 Million |
|
Venzee Technologies Inc
V:VENZ
|
Canada | CA$640.82K |
Liability Composition Analysis (2014–2025)
This chart breaks down Annexin Pharmaceuticals AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Annexin Pharmaceuticals AB market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Annexin Pharmaceuticals AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Annexin Pharmaceuticals AB (2014–2025)
The table below shows the annual total liabilities of Annexin Pharmaceuticals AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr5.22 Million ≈ $562.19K |
-1.86% |
| 2024-12-31 | Skr5.32 Million ≈ $572.84K |
-33.04% |
| 2023-12-31 | Skr7.95 Million ≈ $855.44K |
+21.81% |
| 2022-12-31 | Skr6.53 Million ≈ $702.30K |
+7.71% |
| 2021-12-31 | Skr6.06 Million ≈ $652.05K |
+34.05% |
| 2020-12-31 | Skr4.52 Million ≈ $486.42K |
-0.59% |
| 2019-12-31 | Skr4.55 Million ≈ $489.33K |
-26.52% |
| 2018-12-31 | Skr6.19 Million ≈ $665.93K |
-3.45% |
| 2017-12-31 | Skr6.41 Million ≈ $689.71K |
-18.72% |
| 2016-12-31 | Skr7.88 Million ≈ $848.55K |
+140.18% |
| 2015-12-31 | Skr3.28 Million ≈ $353.30K |
+234.61% |
| 2014-12-31 | Skr981.14K ≈ $105.59K |
-- |
About Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmo… Read more